Dexamethasone Implant Improves Outcomes in Anti-VEGF Refract

Results from the real-world AUSSIEDEX study suggest dexamethasone implant significantly improved anatomic outcomes at 52 weeks and showed no new safety concerns.

Related Keywords

Westmead , New South Wales , Australia , Sydney , Australian , Paul Mitchell , University Of Sydney , Clinical Ophthalmology Eye Health , Westmead Clinical School , Professor Paul , Professor Paul Mitchell , Clinical Ophthalmology , Eye Health ,